Helocyte, Fortress Biotech Subsidiary Announced That The National Cancer Institute Has Awarded A $3.22M Grant To City Of Hope For Clinical Studies Of Triplex, A Cytomegalovirus Vaccine Being Developed By Helocyte And City Of Hope
Portfolio Pulse from Benzinga Newsdesk
Helocyte, a subsidiary of Fortress Biotech, announced that the National Cancer Institute has awarded a $3.22 million grant to City of Hope for clinical studies of Triplex, a cytomegalovirus vaccine being developed by Helocyte and City of Hope.
June 15, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fortress Biotech's subsidiary Helocyte receives a $3.22 million grant from the National Cancer Institute for clinical studies of the Triplex vaccine.
The grant from the National Cancer Institute is a significant financial boost for the development of the Triplex vaccine. This news is likely to have a positive impact on Fortress Biotech's stock price in the short term, as it demonstrates progress in the development of the vaccine and the potential for future revenue generation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100